The price trend for Zymeworks Inc. (ZYME) has been bearish lately and the stock has lost 7.6% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Zymeworks Inc. (ZYME) closed the last trading session at $18.62, gaining 17.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Zymeworks Inc. (NASDAQ:ZYME) on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.

With customers interested in getting more out of their data, the channel data management (CDM) company Zyme is bolstering its partnership with data visualization company Qlik. We delve into where IoT ...

Zyme Solutions said on Monday that it has received new financing. No financial terms were disclosed. Zyme, a provider of cloud-based solutions that is based in Redwood Shores, Calif., is a portfolio ...

Zymeworks Inc. Annual cash flow by MarketWatch. View ZYME net cash flow, operating cash flow, operating expenses and cash dividends.